| 38.09 Data as of May 24 |  -0.14 / -0.37%Today’s Change | 28.12 Today|||52-Week Range 46.00 | +12.49% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $2.6B |
Company Description
Cepheid is a molecular diagnostics company, which develops, manufactures, and markets fully-integrated systems for testing in the clinical market, as well as for application in the company's legacy industrial, biothreat and partner markets. The company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. It operates through two principal systems: GeneXpert and SmartCycler. The GeneXpert system, the company's primary offering in the clinical market, integrates sample preparation in addition to DNA amplification and detection. It is designed for a broad range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Cepheid was founded by Thomas L. Gutshall, William McMillan, Kurt Petersen, Greg Kovacs, and Allen M. Northrup on March 4, 1996 and is headquartered in Sunnyvale, CA.
Employees
Shareholders
| Mutual fund holders | 65.31% |
| Other institutional | 37.09% |
| Individual stakeholders | 3.76% |
Top Executives
| John L. Bishop | Chairman & Chief Executive Officer |
| Humberto Reyes | Chief Operating Officer & Executive Vice President |
| Andrew D. Miller, CPA | Chief Financial Officer & Executive Vice President |
| David H. Persing, MD, PhD | Director, EVP, Chief Medical & Technical Officer |
| Kerry Flom, PhD | Chief Regulatory Officer & Executive VP |
.
